InnoPath Therapeutics is a drug development company developing first-in-class topical therapeutics to treat the tens of millions of people who get Actinic Keratosis and Non-Melanoma Skin Cancer every year. We are accelerating the development of our lead formulation and a portfolio of patents that will be through PII of the FDA process within five years. We are a group of dedicated scientists, physicians, and business professionals with decades of drug development experience. Including successfully introducing more than 125 drugs, biologics, and devices through the FDA process and into patients, and returning more than $1B to shareholders through successful exits. InnoPath Therapeutics will unlock 50 million new patients and $10B of new revenue annually by offering the next generation of novel topical therapeutics that safely and effectively target tumor cells while promoting overall skin health. We are currently in the pre-clinical stag and hitting all of our milestones.